Lakefront Biotherapeutics NV
Business
GALAPAGOS NV is a biotechnology company focused on developing transformative medicines, primarily advancing decentralized cell therapies and selective small molecule therapeutics. It offers CAR-T and TCR-T cell therapy candidates, next‑generation multi‑targeting constructs, a decentralized cell therapy manufacturing platform (xCellit® workflow, Cocoon® integration) and small molecule discovery capabilities including a TYK2 inhibitor. The company operates as a single operating segment organized around cell therapy and small molecule platforms. It conducts research, development and decentralized manufacturing in Europe and the U.S., and distributes through collaborations, CDMO partnerships and licensing arrangements.
Summary from filing dated 2025-03-27
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $320.88M |
| Total assets | $3.41B |
| Total liabilities | $170.65M |
| Stockholders' equity | — |
| Operating cash flow | — |